Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Market volatility and near-term uncertainty can be challenging to deal with these days -- or at any time. Let's consider four ...

Ozempic is what's known as a GLP-1, a drug class that's prescribed to manage Type 2 diabetes and is effective for weight loss ...

Compounding pharmacies suffered another blow yesterday, as a federal judge sided with the FDA over its decision last year to ...

Columbia University and NewYork-Presbyterian Hospital agreed to pay $750 million to settle hundreds of sexual abuse claims ...

It was spurred by the Intercept’s disclosure of Musk’s hitherto-secret White House email address: [email protected]. When the Intercept first published Musk’s email address, on March 6, journalist ...

As Stat reports, the federal judge's ruling means patients will lose access to less-expensive versions of Eli Lilly's weight loss drug, as well as diabetes treatment Mounjaro, from compounding ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

When David Ricks became CEO of Eli Lilly, he faced the usual pressures of making the right, albeit risky, bets on the next ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

Eli Lilly and Co. on Thursday announced three executive leadership transitions that the Indianapolis drugmaker said better ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...